India markets close in 1 hour 4 minutes
  • BSE SENSEX

    47,834.65
    -246.02 (-0.51%)
     
  • Nifty 50

    14,328.10
    -78.05 (-0.54%)
     
  • USD/INR

    74.9950
    -0.1150 (-0.15%)
     
  • Dow

    33,815.90
    -321.41 (-0.94%)
     
  • Nasdaq

    13,818.41
    -131.81 (-0.94%)
     
  • BTC-INR

    3,647,142.50
    -418,964.25 (-10.30%)
     
  • CMC Crypto 200

    1,110.88
    -132.17 (-10.63%)
     
  • Hang Seng

    29,078.75
    +323.41 (+1.12%)
     
  • Nikkei

    29,020.63
    -167.54 (-0.57%)
     
  • EUR/INR

    90.4334
    +0.1588 (+0.18%)
     
  • GBP/INR

    104.0599
    +0.1231 (+0.12%)
     
  • AED/INR

    20.3540
    -0.0510 (-0.25%)
     
  • INR/JPY

    1.4365
    +0.0019 (+0.13%)
     
  • SGD/INR

    56.4750
    -0.0570 (-0.10%)
     

bluebird bio to Present at Cowen Health Care Conference

·2-min read

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Cowen 41st Annual Health Care Conference, Wednesday, March 3, at 2:40 p.m. ET.

To access the live webcast of bluebird bio’s presentation, please visit the "Events & Presentations" page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird bio website for 90 days following the event.

About bluebird bio, Inc.

bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene and cell therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.

bluebird bio is a human company powered by human stories. We’re putting our care and expertise to work across a spectrum of disorders: cerebral adrenoleukodystrophy, sickle cell disease, β-thalassemia and multiple myeloma, using gene and cell therapy technologies including gene addition, and (megaTAL-enabled) gene editing.

bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit bluebirdbio.com.

Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.

bluebird bio is a trademark of bluebird bio, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210226005333/en/

Contacts

Investors & Media

Investors:

Ingrid Goldberg, 857-217-0490
igoldberg@bluebirdbio.com

Elizabeth Pingpank, 617-914-8736
epingpank@bluebirdbio.com

Media:

Jenn Snyder, 617-448-0281
jsnyder@bluebirdbio.com

Catherine Falcetti, 617-583-3411
cfalcetti@bluebirdbio.com